Interplay of n-3 Polyunsaturated Fatty Acids, Intestinal Inflammation, and Gut Microbiota in Celiac Disease Pathogenesis
Nutrients · 2025
DOI: 10.3390/nu17040621 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Nutrients, 2025. Verfasst von Karla A Bascuñán und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nutrition, Faculty of Medicine, University of Chile, Santiago 8380453, Chile. Hauptthemen laut MEDLINE: Celiac Disease, Gastrointestinal Microbiome, Fatty Acids, Omega-3, Inflammation. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 104 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Chilean National Research and Development Agency (ANID).
Abstract (Originalsprache)
Celiac disease (CD) is a chronic autoimmune disorder driven by both genetic and environmental factors, with the HLA DQ2/DQ8 genotypes playing a central role in its development. Despite the genetic predisposition, only a small percentage of individuals carrying these genotypes develop the disease. Gluten, a protein found in wheat, rye, and barley, is the primary environmental trigger, but other factors, such as the intestinal microbiota, may also contribute to disease progression. While the gluten-free diet (GFD) remains the cornerstone of treatment, many CD patients experience persistent inflammation and gut dysbiosis, leading to ongoing symptoms and complications. This chronic inflammation, which impairs nutrient absorption, increases the risk of malnutrition, anemia, and other autoimmune disorders. Recent studies have identified an altered gut microbiota in CD patients, both on and off the GFD, highlighting the potential role of the microbiota in disease pathogenesis. An emerging area of interest is the supplementation of n-3 polyunsaturated fatty acids (PUFAs), known for their anti-inflammatory properties, as a potential therapeutic strategy. n-3 PUFAs, found in fish oil and certain plant oils, modulate the immune cell function and cytokine production, making them a promising intervention for controlling chronic inflammation in CD. This review explores the current understanding of n-3 PUFAs’ effects on the gut microbiota’s composition and inflammation in CD, with the goal of identifying new avenues for complementary treatments to improve disease management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nutrition, Faculty of Medicine, University of Chile, Santiago 8380453, Chile.
- Institute of Nutrition and Food Technology (INTA), University of Chile, Santiago 7830490, Chile.
- Center for Prevention and Diagnosis of Celiac Disease, Gastroenterology and Endoscopy Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy.
- Department of Biomedical, Surgical and Dental Sciences, University of Milan, 20122 Milan, Italy.
- Department of Pathophysiology and Transplantation, Università degli Studi di Milano, 20122 Milan, Italy.
ORCID-Profile: Karla A Bascuñán, Luca Elli, Rodrigo Valenzuela
Förderung
- Chilean National Research and Development Agency (ANID)
Zitieren
APA
Bascuñán, K. A., Araya, M., Rodríguez, J. M., Roncoroni, L., Elli, L., Alvarez, J. D. P. L., & Valenzuela, R. (2025). Interplay of n-3 Polyunsaturated Fatty Acids, Intestinal Inflammation, and Gut Microbiota in Celiac Disease Pathogenesis. Nutrients. https://doi.org/10.3390/nu17040621
Vancouver
Bascuñán KA, Araya M, Rodríguez JM, Roncoroni L, Elli L, Alvarez JDPL, et al. Interplay of n-3 Polyunsaturated Fatty Acids, Intestinal Inflammation, and Gut Microbiota in Celiac Disease Pathogenesis. Nutrients. 2025. doi:10.3390/nu17040621
BibTeX
@article{Bascun2025,
author = {Bascuñán, Karla A and Araya, Magdalena and Rodríguez, Juan Manuel and Roncoroni, Leda and Elli, Luca and Alvarez, Josefina Del Pilar López and Valenzuela, Rodrigo},
title = {Interplay of n-3 Polyunsaturated Fatty Acids, Intestinal Inflammation, and Gut Microbiota in Celiac Disease Pathogenesis},
journal = {Nutrients},
year = {2025},
doi = {10.3390/nu17040621}
}
EUVIMED